Can Johnson & Johnson beat and raise?


Johnson & Johnson Inc. (NYSE:JNJ) will report earnings for the fourth quarter on January 23rd. It looks like it will be able to meet expectations but I don't think it will raise guidance.

JNJ is 230 separate companies in fields ranging from bandages to pharmaceuticals. With $52 billion in sales and $11 billion in profits, it's best known for its corporate citizenship. As I noted in Value Leadership, JNJ put its credo to the test in 1982 when seven people died in Chicago after ingesting cyanide-laced Tylenol. JNJ immediately pulled all the bottles from stores around the country and reintroduced the product with tamper-proof seals six weeks later. The decision to pull the 31 million bottles at a cost of $100 million was made by managers without consulting the CEO, who was unreachable in an airplane at the time.

Eighteen analysts who cover JNJ expect it to earn 80 cents a share in the fourth quarter and $3.74 for the full year 2006. These estimates are 8.9% and 6.9% higher, respectively, than during the same period in 2005. According to Forbes, The Goldman Sachs Group (NYSE: GS) believes that JNJ is likely to be able to weather the storm that will take place in mid-2007 due to a Medicare Drug Benefit anniversary which is anticipated to dampen volume growth. Goldman believes that with its June 2006 $16.6 billion acquisition of Pfizer Inc.'s (NYSE: PFE) Consumer Healthcare business -- which features strong brands such as Listerine and Nicorette -- JNJ will suffer less than pure-play pharmaceutical companies.

But at a P/E of 18, JNJ is trading 2.7 times higher than its forecast earnings growth rate of 6.7%. An earnings miss or tepid guidance could poison JNJ stock. Will JNJ miss-and-lower, meet-and-maintain, or beat-and-raise?

Peter Cohan is President of Peter S. Cohan & Associates, a management consulting and venture capital firm, a Professor of Management at Babson College, and editor of The Cohan Letter. He has no financial interest in Goldman Sachs, Johnson & Johnson. or Pfizer securities.

Also check out some other earnings reports that we're following, and let us know your thoughts on earnings expectations.

Symbol Lookup
IndexesChangePrice
DJIA-89.2312,801.23
NASDAQ-23.352,903.88
S&P 500-9.311,342.64

Last updated: February 12, 2012: 10:11 PM

Hot Stocks

General Electric

18.875-0.255(-1.33)

Alcoa

10.29-0.35(-3.29)

Apple Inc

493.42+0.25(+0.05)

Google Inc 'A'

605.91-5.55(-0.91)

Bank of America

8.07-0.11(-1.34)

Wal-Mart Stores

61.90-0.06(-0.10)

Exxon Mobil Corp

83.80-1.08(-1.27)

Ford

12.44-0.25(-1.97)

Citigroup

32.925-0.735(-2.18)

IBM

192.42-0.71(-0.37)

Yahoo

16.14+0.14(+0.88)

Starbucks

48.82-0.38(-0.77)

Microsoft

30.495-0.275(-0.89)

Home Depot

45.33+0.06(+0.13)

DailyFinance Headlines

Benzinga Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

DailyFinance BlackBerry App

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

BioHealth Investor Headlines

Page Loaded in 1329102712583 ms.